Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
List view / Grid view
In pre-clinical trials, researchers have shown that a new vaccine could combat the dangerous effects of synthetic cannabinoids.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
A study suggests there may be common genetic pathways between alcohol use disorder and other addictions, so GWAS identification of affected genes could provide the targets for new therapies.
Researchers have discovered that a very common protein in the brain has an additional significant role in addiction relapse...
Hormones that signal the body's state of hunger and fullness could be the key to new treatments for drug and alcohol addiction...
Cannabidiol shown to affect emotion and emotional memory
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
A research group has identified an enzyme, PRDM2, whose production is turned off in nerve cells of the frontal lobe when alcohol dependence develops...